Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Aug 1;69(4):676-686.
doi: 10.1093/cid/ciy966.

Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression

Martin Hoenigl  1   2   3 , Carlee B Moser  4 , Nicholas Funderburg  5 , Ronald Bosch  4 , Amy Kantor  4 , Yonglong Zhang  6 , Jesper Eugen-Olsen  7 , Malcolm Finkelman  6 , Jochen Reiser  8 , Alan Landay  9 , Daniela Moisi  10 , Michael M Lederman  10 , Sara Gianella  1 ; Adult Clinical Trials Group NWCS 411 study team
Affiliations
Observational Study

Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression

Martin Hoenigl et al. Clin Infect Dis. .

Abstract

Background: Despite effective antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection remains associated with higher morbidity and mortality, driven, in part, by increased inflammation. Our objective was to identify associations between levels of plasma biomarkers of chronic inflammation, microbial translocation, and monocyte activation, with occurrence of non-AIDS events.

Methods: Participants (141 cases, 310 matched controls) were selected from a longitudinal observational trial; all were virally suppressed on ART at year 1 and thereafter. Soluble urokinase plasminogen activator receptor (suPAR), lipopolysaccharide binding protein (LBP), beta-D-glucan (BDG), intestinal fatty-acid binding protein, oxidized low-density lipoproteins, and soluble CD163 were measured pre-ART, after 1-year of ART, and pre-event. At each time point, conditional logistic regression analysis assessed associations of the biomarkers with events and adjusted for relevant covariates to calculate odds ratios (ORs) according to 1 interquartile range (IQR) difference.

Results: At all time points, higher levels of suPAR were associated with increased risk of non-AIDS events (OR per 1 IQR was 1.7 before ART-initiation, OR per 1 IQR was 2.0 after 1 year of suppressive ART, and OR 2.1 pre-event). Higher levels of BDG and LBP at year 1 and pre-event (but not at baseline) were associated with increased risk of non-AIDS events. No associations were observed for other biomarkers.

Conclusions: Elevated levels of suPAR were strongly, consistently, and independently predictive of non-AIDS events at every measured time point. Interventions that target the suPAR pathway should be investigated to explore its role in the pathogenesis of non-AIDS-related outcomes in HIV infection.

Keywords: beta-D-glucan; lipopolysaccharide binding protein; non-AIDS mortality; suPAR; viral suppression.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Distribution of soluble markers of inflammation and coagulation among cases (blue) and controls (black) in specimens obtained at the visit before antiretroviral therapy (ART) initiation (baseline), the visit approximately 1 year after ART initiation (year 1), and the visit immediately preceding the non–AIDS-defining event (pre-event). Jitter blots including median and interquartile range are displayed. For controls, all differences between baseline and year-1 were significant (ie, P < .05) except for soluble urokinase plasminogen activator receptor. Abbreviations: BDG, beta-D-glucan; I-FABP, intestinal fatty acid binding protein; LBP, lipopolysaccharide binding protein; oxLDL, oxidized low-density lipoproteins; sCD163, soluble CD163; suPAR, soluble urokinase plasminogen activator receptor.
Figure 2.
Figure 2.
Heat map of Spearman correlations between biomarkers in controls. P values <.05 are indicated with a dot. Abbreviations: BDG, beta-D-glucan; I-FABP, intestinal fatty acid binding protein; LBP, lipopolysaccharide binding protein; oxLDL, oxidized low-density lipoproteins; sCD163, soluble CD163; suPAR, soluble urokinase plasminogen activator receptor.
Figure 3.
Figure 3.
Biomarker levels at baseline and odds ratios of having a non–AIDS-defining event. Unadjusted analyses adjusted for the matching factors only. Adjusted analyses controlled also for concurrent log10 baseline human immunodeficiency virus RNA load or smoking. Abbreviations: BDG, beta-D-glucan; CI, confidence interval; HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; IQR, interquartile range; LBP, lipopolysaccharide binding protein; MI, myocardial infarction; OR, odds ratio; oxLDL, oxidized low-density lipoproteins; sCD163, soluble CD163; suPAR, soluble urokinase plasminogen activator receptor. *.01 ≤ P value < .05.
Figure 4.
Figure 4.
Biomarker levels obtained at the visit approximately 1 year after antiretroviral therapy initiation (year 1) and odds ratios of having a non–AIDS-defining event. Unadjusted analyses adjusted for the matching factors only. Adjusted analyses controlled also for concurrent CD4+ T-cell count (adjustment includes quadratic and cubic terms) or smoking. Abbreviations: BDG, beta-D-glucan; CI, confidence interval; HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; IQR, interquartile range; LBP, lipopolysaccharide binding protein; MI, myocardial infarction; OR, odds ratio; oxLDL, oxidized low-density lipoproteins; sCD163, soluble CD163; suPAR, soluble urokinase plasminogen activator receptor. *.01 ≤ P value < .05, **P value < .01.
Figure 5.
Figure 5.
Biomarker obtained at the visit immediately preceding the non–AIDS-defining event (pre-event) and odds ratios of having a non–AIDS-defining event. Adjusted analyses controlled also for concurrent CD4+ T-cell count (adjustment includes quadratic and cubic terms) or smoking. Abbreviations: BDG, beta-D-glucan; CI, confidence interval; HIV, human immunodeficiency virus; I-FABP, intestinal fatty acid binding protein; IQR, interquartile range; LBP, lipopolysaccharide binding protein; MI, myocardial infarction; OR, odds ratio; oxLDL, oxidized low-density lipoproteins; sCD163, soluble CD163; suPAR, soluble urokinase plasminogen activator receptor. *P = .01 to <.05; **P < .01.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Palella FJ Jr , Baker RK , Moorman AC , et al. ; HIV Outpatient Study Investigators Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27–34. - PubMed
    1. Wester CW , Koethe JR , Shepherd BE , et al. . Non-AIDS-defining events among HIV-1-infected adults receiving combination antiretroviral therapy in resource-replete versus resource-limited urban setting. AIDS 2011; 25:1471–9. - PMC - PubMed
    1. Krishnan S , Schouten JT , Jacobson DL , et al. ; ACTG-ALLRT Protocol Team Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis. Oncology 2011; 80:42–9. - PMC - PubMed
    1. Angelidou K , Hunt PW , Landay AL , et al. . Changes in inflammation but not in T cell activation precede non-AIDS-defining events in a case-control study of patients on long-term antiretroviral therapy. J Infect Dis 2017. doi: 10.1093/infdis/jix666. - DOI - PMC - PubMed
    1. Hunt PW. HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 2012; 9:139–47. - PubMed

Publication types

Substances